WKEY vs IDAI vs CEVA vs XTLB vs AMAT

For growth investors, CEVA, Inc.

(CEVA) is the stronger pick with 9. 8% revenue growth year-over-year, versus -61. 6% for WISeKey International Holding AG (WKEY). Applied Materials, Inc. (AMAT) offers the better valuation at 47. 4x trailing P/E (39. 3x forward), making it the more compelling value choice. Analysts rate CEVA, Inc. (CEVA) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Applied Materials, Inc.

is actually cheaper at 39. 3x.

Over the past 5 years, Applied Materials, Inc.

(AMAT) delivered a total return of +213. 8%, compared to -99. 1% for T Stamp Inc. (IDAI). Over 10 years, the gap is even starker: AMAT returned +21. 4% versus WKEY's -91. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), XTL Biopharmaceuticals Ltd.

(XTLB) is the lower-risk stock at 1. 64β versus WISeKey International Holding AG's 3. 68β — meaning WKEY is approximately 125% more volatile than XTLB relative to the S&P 500. On balance sheet safety, CEVA, Inc. (CEVA) carries a lower debt/equity ratio of 2% versus 130% for T Stamp Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), CEVA, Inc.

(CEVA) is pulling ahead at 9. 8% versus -61. 6% for WISeKey International Holding AG (WKEY). On earnings-per-share growth, the picture is similar: T Stamp Inc. grew EPS 29. 3% year-over-year, compared to 0. 6% for Applied Materials, Inc.. Over a 3-year CAGR, AMAT leads at 3. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Applied Materials, Inc.

(AMAT) is the more profitable company, earning 24. 7% net margin versus -344. 1% for T Stamp Inc. — meaning it keeps 24. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMAT leads at 29. 2% versus -481. 6% for XTLB. At the gross margin level — before operating expenses — CEVA leads at 88. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Applied Materials, Inc.

(AMAT) trades at 39. 3x forward P/E versus 73. 8x for CEVA, Inc. — 34. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AMAT: 6. 5% to $437. 10.

In this comparison, AMAT (0.

4% yield) pays a dividend. WKEY, IDAI, CEVA, XTLB do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, XTL Biopharmaceuticals Ltd.

(XTLB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. WISeKey International Holding AG (WKEY) carries a higher beta of 3. 68 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (XTLB: -87. 9%, WKEY: -91. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (WKEY (Technology) and IDAI (Technology) and CEVA (Technology) and XTLB (Healthcare) and AMAT (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.